KR102262179B1 - 설사를 치료하기 위한 물질 및 방법 - Google Patents

설사를 치료하기 위한 물질 및 방법 Download PDF

Info

Publication number
KR102262179B1
KR102262179B1 KR1020207024016A KR20207024016A KR102262179B1 KR 102262179 B1 KR102262179 B1 KR 102262179B1 KR 1020207024016 A KR1020207024016 A KR 1020207024016A KR 20207024016 A KR20207024016 A KR 20207024016A KR 102262179 B1 KR102262179 B1 KR 102262179B1
Authority
KR
South Korea
Prior art keywords
glucose
composition
therapeutic composition
sterile therapeutic
secretion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207024016A
Other languages
English (en)
Korean (ko)
Other versions
KR20200105525A (ko
Inventor
사다시반 비다사거
폴 오쿠니에프
루롱 장
Original Assignee
유니버시티 오브 플로리다 리서치 파운데이션, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티 오브 플로리다 리서치 파운데이션, 인크. filed Critical 유니버시티 오브 플로리다 리서치 파운데이션, 인크.
Publication of KR20200105525A publication Critical patent/KR20200105525A/ko
Application granted granted Critical
Publication of KR102262179B1 publication Critical patent/KR102262179B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020207024016A 2012-02-08 2013-02-08 설사를 치료하기 위한 물질 및 방법 Active KR102262179B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261596480P 2012-02-08 2012-02-08
US61/596,480 2012-02-08
KR1020147025066A KR20140120941A (ko) 2012-02-08 2013-02-08 설사를 치료하기 위한 물질 및 방법
PCT/US2013/025294 WO2013119917A1 (en) 2012-02-08 2013-02-08 Materials and methods for treating diarrhea

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020147025066A Division KR20140120941A (ko) 2012-02-08 2013-02-08 설사를 치료하기 위한 물질 및 방법

Publications (2)

Publication Number Publication Date
KR20200105525A KR20200105525A (ko) 2020-09-07
KR102262179B1 true KR102262179B1 (ko) 2021-06-07

Family

ID=48948047

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207024016A Active KR102262179B1 (ko) 2012-02-08 2013-02-08 설사를 치료하기 위한 물질 및 방법
KR1020147025066A Ceased KR20140120941A (ko) 2012-02-08 2013-02-08 설사를 치료하기 위한 물질 및 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020147025066A Ceased KR20140120941A (ko) 2012-02-08 2013-02-08 설사를 치료하기 위한 물질 및 방법

Country Status (15)

Country Link
US (4) US20140377374A1 (enExample)
EP (1) EP2812007B1 (enExample)
JP (1) JP6084238B2 (enExample)
KR (2) KR102262179B1 (enExample)
CN (1) CN104093410B (enExample)
AP (1) AP3941A (enExample)
AU (1) AU2013216871B2 (enExample)
BR (1) BR112014019350B1 (enExample)
CA (1) CA2863388C (enExample)
EA (1) EA034014B1 (enExample)
ES (1) ES2862392T3 (enExample)
HK (1) HK1204290A1 (enExample)
IN (1) IN2014DN06737A (enExample)
MX (1) MX368543B (enExample)
WO (1) WO2013119917A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2624825B1 (en) 2010-09-24 2017-06-14 University of Florida Research Foundation, Inc. Materials and methods for improving gastrointestinal function
JP6378307B2 (ja) 2013-03-11 2018-08-22 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 肺機能を改善するためならびに放射線誘発肺合併症の予防および／または処置のための物質および方法
BR112017010832A2 (pt) 2014-11-24 2017-12-26 Entrinsic Health Solutions Llc composições de aminoácido para o tratamento de sintomas de doença
MX2019003821A (es) 2016-10-04 2019-12-18 Univ Florida Composiciones de aminoacidos y usos de las mismas.
WO2019070753A1 (en) * 2017-10-02 2019-04-11 University Of Florida Research Foundation, Incorporated AMINO ACID COMPOSITIONS AND METHODS FOR TREATING DIARRHEA
IL298743A (en) * 2020-06-02 2023-02-01 Univ Florida Formulations and methods for treating diarrhea
WO2022006397A1 (en) * 2020-07-02 2022-01-06 University Of Florida Research Foundation, Incorporated Formulations for promoting hydration and methods of use thereof
US20240252580A1 (en) * 2021-05-28 2024-08-01 The Coca-Cola Company Amino acid hydration formulation and method of use
CN115531363B (zh) * 2021-06-30 2024-03-29 中国科学技术大学 预防、抑制或治疗轮状病毒感染的药物组合物及其用途
US11878073B1 (en) 2022-09-20 2024-01-23 Entrinsic, LLC Generation of hydration-targeted formulations and methods of use therein

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030143293A1 (en) 2002-01-31 2003-07-31 Sergei Shushunov Compositions and methods for treating diarrhea
JP2004123642A (ja) 2002-10-04 2004-04-22 Shimizu Pharmaceutical Co Ltd 電解質組成物
JP2006511504A (ja) 2002-11-11 2006-04-06 ファーマレット エイ／エス 治療薬として使用するための製薬
JP2006304775A (ja) 2005-03-31 2006-11-09 Ajinomoto Co Inc 水分電解質補給飲料
JP2007068466A (ja) 2005-09-07 2007-03-22 Wakoudou Kk 液体飲料組成物及びその製造方法
WO2012040707A2 (en) 2010-09-24 2012-03-29 University Of Florida Research Foundation, Inc. Materials and methods for improving gastrointestinal function

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5290538A (en) * 1988-12-22 1994-03-01 Skrezek Christian Nephro protective infusion solutions
JP3301646B2 (ja) * 1993-03-19 2002-07-15 シスメックス株式会社 幼若細胞測定用試薬
KR19980703876A (ko) * 1995-04-14 1998-12-05 스티븐 엘. 허스트 분산성이 개선된 분말화된 약학적 조성물
JP4255656B2 (ja) * 2001-09-17 2009-04-15 株式会社メニコン 眼科用液剤及びコンタクトレンズ用液剤
US20050100637A1 (en) * 2003-11-12 2005-05-12 Robert Murray Carbohydrate and electrolyte replacement composition
GB0503337D0 (en) * 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
DE102006018293A1 (de) * 2006-04-20 2007-10-25 Fresenius Kabi Deutschland Gmbh Pädiatrische Aminosäurelösung zur parenteralen Ernäherung
JP6378307B2 (ja) * 2013-03-11 2018-08-22 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 肺機能を改善するためならびに放射線誘発肺合併症の予防および／または処置のための物質および方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030143293A1 (en) 2002-01-31 2003-07-31 Sergei Shushunov Compositions and methods for treating diarrhea
JP2004123642A (ja) 2002-10-04 2004-04-22 Shimizu Pharmaceutical Co Ltd 電解質組成物
JP2006511504A (ja) 2002-11-11 2006-04-06 ファーマレット エイ／エス 治療薬として使用するための製薬
JP2006304775A (ja) 2005-03-31 2006-11-09 Ajinomoto Co Inc 水分電解質補給飲料
JP2007068466A (ja) 2005-09-07 2007-03-22 Wakoudou Kk 液体飲料組成物及びその製造方法
WO2012040707A2 (en) 2010-09-24 2012-03-29 University Of Florida Research Foundation, Inc. Materials and methods for improving gastrointestinal function
KR101758424B1 (ko) 2010-09-24 2017-07-14 유니버시티 오브 플로리다 리서치 파운데이션, 인크. 위장 기능을 증진시키기 위한 물질 및 방법

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. Health Popul. Nutr., 25(3), pp.278-284(2007) 1부.*

Also Published As

Publication number Publication date
JP6084238B2 (ja) 2017-02-22
US20250073260A1 (en) 2025-03-06
EP2812007A1 (en) 2014-12-17
BR112014019350A8 (pt) 2017-07-11
KR20140120941A (ko) 2014-10-14
KR20200105525A (ko) 2020-09-07
WO2013119917A1 (en) 2013-08-15
US20210299076A1 (en) 2021-09-30
EP2812007B1 (en) 2020-12-30
EP2812007A4 (en) 2015-09-09
CA2863388C (en) 2020-11-17
JP2015506981A (ja) 2015-03-05
CN104093410B (zh) 2018-04-27
US20150297636A1 (en) 2015-10-22
US20140377374A1 (en) 2014-12-25
CA2863388A1 (en) 2013-08-15
IN2014DN06737A (enExample) 2015-05-22
AU2013216871A1 (en) 2014-09-11
CN104093410A (zh) 2014-10-08
EA201400827A1 (ru) 2014-12-30
ES2862392T3 (es) 2021-10-07
MX2014009557A (es) 2014-11-10
BR112014019350A2 (enExample) 2017-06-20
AP2014007916A0 (en) 2014-09-30
AU2013216871B2 (en) 2017-08-17
MX368543B (es) 2019-10-07
AP3941A (en) 2016-12-16
HK1204290A1 (en) 2015-11-13
BR112014019350B1 (pt) 2020-09-24
EA034014B1 (ru) 2019-12-19

Similar Documents

Publication Publication Date Title
US20250073260A1 (en) Amino acid formulations and uses thereof
Hurtado et al. Neuroprotection afforded by prior citicoline administration in experimental brain ischemia: effects on glutamate transport
KR102069790B1 (ko) 위장 기능을 증진시키기 위한 물질 및 방법
Schaffer et al. Effect of taurine and potential interactions with caffeine on cardiovascular function
Zeevalk et al. Chemically induced hypoglycemia and anoxia: relationship to glutamate receptor-mediated toxicity in retina.
Holecek Side effects of long‐term glutamine supplementation
PT2214480E (pt) Métodos de tratamento de esteato-hepatite não alcoólica (nash) utilizando produtos de cisteamina
Han et al. β-Cell-protective effect of 2-aminobicyclo-(2, 2, 1)-heptane-2-carboxylic acid as a glutamate dehydrogenase activator in db/db mice
de Souza Goncalves et al. Mg 2+ supplementation treats secretory diarrhea in mice by activating calcium-sensing receptor in intestinal epithelial cells
Fraternale et al. Inhibition of murine AIDS by pro-glutathione (GSH) molecules
Slinko et al. Combined zinc supplementation with proinsulin C-peptide treatment decreases the inflammatory response and mortality in murine polymicrobial sepsis
JP5244597B2 (ja) カルシリティック化合物またはカルシウム模倣性化合物を用いて腸液バランスを調節する方法
CN117427083A (zh) 阿洛酮糖在制备治疗阿尔兹海默病药物中的应用及药物
US11826334B2 (en) Antiviral therapeutic compounds and compositions for use in treatment of coronavirus and influenza virus
Guthrie et al. Impact of Parenteral Lipid Emulsion Components on Cholestatic Liver Disease in Neonates. Nutrients 2021, 13, 508
GOLDBERG DEVELOPMENTAL DEFECTS OF BROWN ADIPOSE TISSUE IN OBESE (FAFA) ZUCKER RATS: A DIRECT RESULT OF THE" FA"(FAT) GENE
Tang et al. T1739 Selective Regulation of Na+-K+-2cl− Cotransporter Surface Expression and Epithelial Cl− Secretion By Novel Protein Kinase C (PKC) Isoforms δ and ɛ
Rodrigues et al. P267 Receptor in the Kidneys of Diabetic Rats Submitted to

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200820

Application number text: 1020147025066

Filing date: 20140905

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20201005

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210310

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210602

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210602

End annual number: 3

Start annual number: 1

PG1601 Publication of registration